Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

| Create an account https://orcid.org

Search life-sciences literature (45,100,050 articles, preprints and more)

Suggested authors matching "AUTH:Ofran Y" with an ORCID

Yishai Ofran
Rambam Health Care Campus
54
Publications
1,477
Citations
View profile

Search results

1-25 of 169 results

Sort by:

Relevance ^{Relevance: This is determined based on a ranking of criteria including term frequency, rarity of term, recency of article, whether there is a Title or Author field match, etc.}

Times cited

Date

1 2 3 Next ...

Interactions between immune cell types facilitate the evolution of immune traits.
Dubovik T, Lukačišin M, Starosvetsky E, LeRoy B, Normand R, Admon Y, Alpert A, Ofran Y, G'Sell M, Shen-Orr SS
Nature, 632(8024):350-356, 12 Jun 2024
Cited by: 0 articles | PMID: 38866051 | PMCID: PMC11306095
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemia.
Kugler E, Cohen I, Amitai I, Ram R, Frisch A, Nachmias B, Canaani J, Moshe Y, Krayem B, Aumann S, Henig I, Vainstein V, Shargian L, Ganzel C, Yeshurun M, Levi I, Raanani P, Akria L, Ofran Y, [...] Wolach O
Br J Haematol, 205(3):932-941, 23 May 2024
Cited by: 1 article | PMID: 38782575
Add to export list
Intensive induction in older patients with acute myeloid leukemia: an initial struggle with later rewards?
Ofran Y
Haematologica, 109(5):1331-1333, 01 May 2024
Cited by: 0 articles | PMID: 38299567 | PMCID: PMC11063846
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
The effect of mind-body intervention on lymphocyte doubling time and treatment free survival in treatment-naïve chronic lymphocytic leukemia patients.
Shapira S, Hirschberger N, Ofran Y, Mizrahi B, Mandel E, Benjamini O, Rabinowicz N, Zoref-Lorenz A
Acta Haematol, 08 Mar 2024
Cited by: 0 articles | PMID: 38461815
Add to export list
CAGI, the Critical Assessment of Genome Interpretation, establishes progress and prospects for computational genetic variant interpretation methods.
Critical Assessment of Genome Interpretation Consortium
Genome Biol, 25(1):53, 22 Feb 2024
Cited by: 19 articles | PMID: 38389099 | PMCID: PMC10882881
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Is it time for age and clinically adjusted minimal residual disease interpretation in acute myeloid leukemia?
Ofran Y
Haematologica, 109(1):6-7, 01 Jan 2024
Cited by: 0 articles | PMID: 37534509 | PMCID: PMC10772512
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
The Effect of Oral Iron Chelator Deferiprone on Iron Overload and Oxidative Stress in Patients with Myelodysplastic Syndromes: A Study by the Israeli MDS Working Group.
Merkel D, Soffer S, Filanovsky K, Braester A, Fibach E, Dana M, Ofran Y, Greenbaum U, Nagler A, Amitai I, Mittelman M
Acta Haematol, 147(4):427-434, 16 Dec 2023
Cited by: 0 articles | PMID: 38104534 | PMCID: PMC11296558
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study.
Pabst T, Papayannidis C, Demirkan F, Doronin V, Fogliatto LM, Guttke C, Gyan E, Hamad N, Herrera P, Hultberg A, Jacobs J, Johnson AJ, Langlois A, Ma X, Martinelli G, Arnan M, Müller R, Nottage K, Ofran Y, [...] Wei AH
Lancet Haematol, 10(11):e902-e912, 01 Nov 2023
Cited by: 0 articles | PMID: 37914483
Add to export list
Interactions between immune cell types facilitate the evolution of immune traits
Dubovik T, Lukačišin M, Starosvetsky E, LeRoy B, Normand R, Admon Y, Alpert A, Ofran Y, G'Sell M, Shen-Orr SS
Research Square, 18 Oct 2023
Cited by: 0 articles | PPR: PPR744436
Add to export list Preprint v1
"Redirecting an anti-IL-1β antibody to bind a new, unrelated and computationally predicted epitope on hIL-17A".
Fischman S, Levin I, Rondeau JM, Štrajbl M, Lehmann S, Huber T, Nimrod G, Cebe R, Omer D, Kovarik J, Bernstein S, Sasson Y, Demishtein A, Shlamkovich T, Bluvshtein O, Grossman N, Barak-Fuchs R, Zhenin M, Fastman Y, [...] Ofran Y
Commun Biol, 6(1):997, 29 Sep 2023
Cited by: 1 article | PMID: 37773269 | PMCID: PMC10542344
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Chasing quality remission in acute myeloid leukemia: intensity of induction and residual disease.
Ofran Y
Haematologica, 108(8):1973-1974, 01 Aug 2023
Cited by: 0 articles | PMID: 37525958 | PMCID: PMC10388263
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
PB1941: MIND-BODY INTERVENTION PROLONGS LYMPHOCYTE DOUBLING TIME AND TREATMENT-FREE SURVIVAL IN TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS
Shapira S, Lorenz A, Hirschberger N, Mizrahi B, Benjamini O, Mandel E, Ofran Y
Hemasphere, 7(suppl ), 01 Aug 2023
Cited by: 0 articles | PMCID: PMC10430259
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Computational Engineering of a Therapeutic Antibody to Inhibit Multiple Mutants of HER2 Without Compromising Inhibition of the Canonical HER2
Peled S, Guez-Haddad J, Biton NZ, Nimrod G, Fischman S, Fastman Y, Ofran Y
bioRxiv, 25 Jul 2023
Cited by: 0 articles | PPR: PPR696869
Add to export list Preprint
Decreased melanoma CSF-1 secretion by Cannabigerol treatment reprograms regulatory myeloid cells and reduces tumor progression.
Wyrobnik I, Steinberg M, Gelfand A, Rosenblum R, Eid Mutlak Y, Sulimani L, Procaccia S, Ofran Y, Novak-Kotzer H, Meiri D
Oncoimmunology, 12(1):2219164, 11 Jun 2023
Cited by: 3 articles | PMID: 37325437 | PMCID: PMC10262794
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Venetoclax-based salvage therapy for adult patients with relapsed/refractory acute lymphoblastic leukemia.
Canaani J, Frisch A, Pollyea DA, Schwartz M, Aumann S, Ganzel C, Haran A, Even-Zohar NG, Shaulov A, Vainstein V, Moshe Y, Ofran Y, Wolach O, Nachmias B
Eur J Haematol, 111(3):365-372, 31 May 2023
Cited by: 4 articles | PMID: 37254665
Add to export list
Accurate profiling of full-length Fv in highly homologous antibody libraries using UMI tagged short reads.
Levin I, Štrajbl M, Fastman Y, Baran D, Twito S, Mioduser J, Keren A, Fischman S, Zhenin M, Nimrod G, Levitin N, Mayor MB, Gadrich M, Ofran Y
Nucleic Acids Res, 51(11):e61, 01 Jun 2023
Cited by: 3 articles | PMID: 37014016 | PMCID: PMC10287906
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Antitumoral effects of cannabis in Notch1-mutated T-cell acute lymphoblastic leukemia.
Besser E, Gelfand A, Lewitus GM, Novak-Kotzer H, Procaccia S, Berman P, Louria-Hayon I, Shreiber-Livne I, Ofran Y, Meiri D
Cancer Commun (Lond), 43(6):711-715, 21 Apr 2023
Cited by: 1 article | PMID: 37086009 | PMCID: PMC10259664
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Cushioned Footwear Effect on Pain and Gait Characteristics of Individuals with Knee Osteoarthritis: A Double-Blinded 3 Month Intervention Study.
Schwartz I, Ofran Y, Bernovsky S, Kandel L, Rivkin G, Karniel N, Seyres M, Portnoy S
Sensors (Basel), 23(3):1375, 26 Jan 2023
Cited by: 0 articles | PMID: 36772413 | PMCID: PMC9920540
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
The increasingly blurred line between induction, consolidation and maintenance in acute myeloid leukaemia.
Frisch A, Rowe JM, Ofran Y
Br J Haematol, 200(5):556-562, 26 Dec 2022
Cited by: 0 articles | PMID: 36572392
Add to export list Review
Implementation of data protection laws in the European Union and in California is associated with a move of clinical trials to countries with fewer data protections.
Yom-Tov E, Ofran Y
Front Med (Lausanne), 9:1051025, 10 Nov 2022
Cited by: 0 articles | PMID: 36438038 | PMCID: PMC9685308
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Compromised activity of natural killer cells in diffuse large b-cell lymphoma is related to lymphoma-induced modification of their surface receptor expression.
Azoulay T, Slouzky I, Karmona M, Filatov M, Hayun M, Ofran Y, Sarig G, Ringelstein-Harlev S
Cancer Immunol Immunother, 72(3):707-718, 01 Sep 2022
Cited by: 2 articles | PMID: 36048214 | PMCID: PMC10992952
Add to export list Free full text in Europe PMC
Correction to: Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real‑world, multi‑center, matched analysis.
Shimony S, Canaani J, Kugler E, Nachmias B, Ram R, Henig I, Frisch A, Ganzel C, Vainstein V, Moshe Y, Aumann S, Yeshurun M, Ofran Y, Raanani P, Wolach O
Ann Hematol, 101(9):2011, 01 Sep 2022
Cited by: 0 articles | PMID: 35869985
Add to export list
Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study.
Jonas BA, DiNardo C, Fracchiolla N, Pristupa A, Ishizawa K, Jin J, Konopleva M, Ofran Y, Montesinos P, Kovacsovics T, Jang JH, Kantarjian H, Duan Y, Potluri J, Werner M, Pratz KW
Am J Hematol, 97(11):E422-E425, 16 Sep 2022
Cited by: 4 articles | PMID: 36053878 | PMCID: PMC10286746
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
DistilProtBert: a distilled protein language model used to distinguish between real proteins and their randomly shuffled counterparts.
Geffen Y, Ofran Y, Unger R
Bioinformatics, 38(suppl_2):ii95-ii98, 01 Sep 2022
Cited by: 7 articles | PMID: 36124789
Add to export list
Venetoclax in combination with FLAG-IDA-based protocol for patients with acute myeloid leukemia: a real-world analysis.
Wolach O, Frisch A, Shargian L, Yeshurun M, Apel A, Vainstein V, Moshe Y, Shimony S, Amit O, Bar-On Y, Ofran Y, Raanani P, Nachmias B, Ram R
Ann Hematol, 101(8):1719-1726, 23 Jun 2022
Cited by: 8 articles | PMID: 35732976
Add to export list

1-25 of 169 results

1 2 3 Next ...

Search life-sciences literature (45,100,050 articles, preprints and more)

Suggested authors matching "AUTH:Ofran Y" with an ORCID Suggested authors have linked their articles in Europe PMC to their ORCID iD. Up to two suggested authors with a matching surname and initial are shown, ordered by the total number of publications they have in Europe PMC.

Search results

Partnerships & funding

Suggested authors matching "AUTH:Ofran Y" with an ORCID